|

SAR445877 Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • Sanofi1

Indications

  • Cancer3
  • Microsatellite Stable1
  • FOlfox61
  • SAR4458771
  • Bevacizimab1

Houston, Texas2 trials

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

MD Anderson Cancer Center

Phase 2
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

MD Anderson Cancer Center

Phase 1

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System - Newark- Site Number : 8400011

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.